Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults

Conze D, Brenner C, Kruger CL · Scientific Reports

Clean dose-response for the biochemical target: whole-blood NAD+ rose 22%, 51% and 142% at 100, 300 and 1,000 mg/day within two weeks and stayed up. No flushing, no excess adverse events, no LDL elevation and no disruption of one-carbon metabolism.

Population

Overweight but otherwise healthy men and women

Intervention

Nicotinamide riboside 100, 300 or 1,000 mg/day for 8 weeks

Comparator

Placebo

Limitations

Designed to support an upper intake level, so the endpoints are safety and biochemistry rather than function. Sponsored by ChromaDex, which sells NIAGEN; two authors are company-affiliated.